ATE309783T1 - Einen histamin h 2 antagonisten enthaltende brausezusammensetzung - Google Patents

Einen histamin h 2 antagonisten enthaltende brausezusammensetzung

Info

Publication number
ATE309783T1
ATE309783T1 AT00980395T AT00980395T ATE309783T1 AT E309783 T1 ATE309783 T1 AT E309783T1 AT 00980395 T AT00980395 T AT 00980395T AT 00980395 T AT00980395 T AT 00980395T AT E309783 T1 ATE309783 T1 AT E309783T1
Authority
AT
Austria
Prior art keywords
effortable
histamine
antagonist
composition containing
composition
Prior art date
Application number
AT00980395T
Other languages
English (en)
Inventor
M Mamoun Hussein
John Migton
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE309783T1 publication Critical patent/ATE309783T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00980395T 1999-12-06 2000-11-16 Einen histamin h 2 antagonisten enthaltende brausezusammensetzung ATE309783T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/455,233 US6264984B1 (en) 1999-12-06 1999-12-06 Effervescent histamine H2 antagonist composition
PCT/US2000/031360 WO2001039750A1 (en) 1999-12-06 2000-11-16 Effervescent histamine h2 antagonist composition

Publications (1)

Publication Number Publication Date
ATE309783T1 true ATE309783T1 (de) 2005-12-15

Family

ID=23807966

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00980395T ATE309783T1 (de) 1999-12-06 2000-11-16 Einen histamin h 2 antagonisten enthaltende brausezusammensetzung

Country Status (18)

Country Link
US (1) US6264984B1 (de)
EP (1) EP1237543B1 (de)
JP (1) JP2003515553A (de)
KR (1) KR100795259B1 (de)
CN (1) CN1211077C (de)
AR (1) AR030172A1 (de)
AT (1) ATE309783T1 (de)
AU (1) AU1766101A (de)
BR (1) BR0015779A (de)
CA (1) CA2394902C (de)
CY (1) CY1105495T1 (de)
DE (1) DE60024132T2 (de)
DK (1) DK1237543T3 (de)
ES (1) ES2252078T3 (de)
MX (1) MXPA02005534A (de)
PE (1) PE20010909A1 (de)
WO (1) WO2001039750A1 (de)
ZA (1) ZA200203168B (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1965774A2 (de) * 2005-12-30 2008-09-10 Cogentus Pharmaceuticals, Inc. Orale pharmazeutische formulierungen mit nichtsteroidalen entzündungshemmern und säurehemmern
US9717726B2 (en) * 2013-03-14 2017-08-01 Maregade Rx, LLC Product and method for treating diarrhea
WO2015157729A1 (en) * 2014-04-11 2015-10-15 Wilmink Michael Pharmaceutical formulations an comprising analgesic agent, a nonsteroidal anti-inflammatory agent, a gastric acid production suppressant and an anti-nauseant
CN105997922A (zh) * 2016-06-12 2016-10-12 佛山市腾瑞医药科技有限公司 一种盐酸雷尼替丁泡腾片及其制备方法
EP3558296B1 (de) 2016-12-23 2023-06-28 Maregade RX, LLC Niedrigdosisprodukt und verfahren zur behandlung von durchfall

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2593065B1 (fr) 1986-01-22 1988-09-09 Smith Kline French Lab Couples effervescents, compositions effervescentes d'antagonistes h2 de l'histamine les contenant et leur preparation.
FR2633181B1 (fr) 1988-06-24 1992-01-10 Glaxo Lab Sa Composition pharmaceutique a base de ranitidine et son procede de preparation
DE4027927A1 (de) * 1990-09-04 1992-03-05 Bayer Ag Brausekomponente und verfahren zu ihrer herstellung
CA2061520C (en) 1991-03-27 2003-04-22 Lawrence J. Daher Delivery system for enhanced onset and increased potency
US5503846A (en) * 1993-03-17 1996-04-02 Cima Labs, Inc. Base coated acid particles and effervescent formulation incorporating same
EP0717614B1 (de) 1993-09-09 1998-11-25 Gergely, Gerhard, Dr. Brausegranulat und verfahren zu seiner herstellung
WO1995010274A1 (en) 1993-10-14 1995-04-20 F.H. Faulding & Co. Limited Aqueous pharmaceutical composition
DE69419492T2 (de) 1994-03-01 2000-02-03 Gerhard Gergely Ein Brausesystem und einen Arzneiwirkstoff enthaltendes granuläres Produkt bzw. Tablette sowie Verfahren zu deren Herstellung
IL112779A (en) 1994-03-01 1999-11-30 Gergely Gerhard Granular product or tablet containing an efferescent system and an active pharmaceutical substance and its preparation
US5824339A (en) 1995-09-08 1998-10-20 Takeda Chemical Industries, Ltd Effervescent composition and its production
US5728401A (en) * 1997-04-16 1998-03-17 Ranbaxy Laboratories, Ltd. Effervescent ranitidine formulations

Also Published As

Publication number Publication date
BR0015779A (pt) 2002-07-09
PE20010909A1 (es) 2001-11-11
CN1407885A (zh) 2003-04-02
WO2001039750A1 (en) 2001-06-07
US6264984B1 (en) 2001-07-24
CA2394902C (en) 2006-08-08
EP1237543A4 (de) 2004-06-30
JP2003515553A (ja) 2003-05-07
KR20020070309A (ko) 2002-09-05
CN1211077C (zh) 2005-07-20
MXPA02005534A (es) 2002-11-29
DE60024132D1 (de) 2005-12-22
EP1237543B1 (de) 2005-11-16
CA2394902A1 (en) 2001-06-07
ZA200203168B (en) 2003-09-23
EP1237543A1 (de) 2002-09-11
ES2252078T3 (es) 2006-05-16
DK1237543T3 (da) 2006-01-16
KR100795259B1 (ko) 2008-01-15
AU1766101A (en) 2001-06-12
CY1105495T1 (el) 2010-04-28
DE60024132T2 (de) 2006-08-03
AR030172A1 (es) 2003-08-13

Similar Documents

Publication Publication Date Title
EG24533A (en) Piperdine derivatives useful as CCR 5 antagonists
IL145741A0 (en) Piperazine derivatives useful as ccrs antagonists
EP1206262A4 (de) Neuropeptid-y antagonisten: derivate des spiroisoquinolinons
EP1268688A4 (de) Tintenzusammensetzungen
EP1147107A4 (de) Angiogeneseinhibitoren
DE60023061D1 (de) Bohrlochpacker
EP1181122A4 (de) Legierungswerkstoffe
NO20012411D0 (no) Pyrrolidin-derivater-CCR-3-reseptorantagonister
EP1074769A4 (de) Dichtungsanordnung
NO991563D0 (no) N-substituerte azaheterosykliske forbindelser
ITMI912182A1 (it) Composti eterociclici ad attivita' a ii antagonista
IL144720A0 (en) Heterocyclic benzenesulphonamide compounds as bradykinine antagonists
ID26665A (id) Antagonis vla-4
EP1249482A4 (de) Aerosolzusammensetzung
IS6126A (is) Nýjar lyfjasamsetningar fyrir NOS lata
ID27845A (id) Turunan tetrahidrokuilina sebagai antagonis glisilina
NO991564D0 (no) N-substituerte azaheterosykliske forbindelser
ATE277912T1 (de) Pyrimidine-2,4,6-trione als matrixmetalloproteinase-hemmer
ATE264301T1 (de) Muscarin-antagonisten
EP1153612A4 (de) Verstarker von antikrebs mitteln
ATE309783T1 (de) Einen histamin h 2 antagonisten enthaltende brausezusammensetzung
EP1192168A4 (de) Galektin
FI943359A7 (fi) Atsasykliset-heterosykliset yhdisteet angiotensiini II reseptoriantagonisteina
FR2797350B1 (fr) Plaque d'electrode pour accumulateur
PT1189600E (pt) Composicoes farmaceuticas liofilizadas contendo grf

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1237543

Country of ref document: EP

EEIH Change in the person of patent owner